日本語 
Quastella Inc., a startup in Nagoya, has raised 110 million yen. They got this funding through a third-party allotment and a loan from The Juroku Bank. The funding round included investments from Aichi Startup Fund No. 1 and Data Driven Innovation Investment, managed by Aichi Capital and epiST Ventures.
The company creates Cytometa. It’s an AI-powered quality control system for cell manufacturing. Traditionally, skilled technicians inspected cell quality. This method often leads to inconsistencies. It’s hard to scale up, and subtle defects can be missed. Cytometa tackles these challenges with a standard, image-based evaluation system. This system measures cell quality during production in a clear, quantitative way.
To help with adoption, Quastella provides a Proof-of-Concept (PoC) support service. This service assists manufacturers in customizing the AI system for their unique processes. It covers culture methods, imaging tools, and cell types. This dual offering seeks to lower barriers to using AI. These barriers often include worries about data needs and doubts about how well custom AI models work in real life.
Also Read: NTT-AT’s WinActor 7.6.0 Boosts AI Integration and Use
The innovation shows a wider trend in the industry. It focuses on automating quality assurance in biomanufacturing. This change aims to boost consistency, scalability, and efficiency.
English